TPS1129 Background: ET+CDK4/6i is standard-of-care (SOC) in 1L ER+/HER2- aBC; however, tumors eventually develop resistance. Constitutive activation in the PI3K/AKT/mTOR pathway can contribute to endocrine resistance in breast cancer. ESR1 mutations are a common type of acquired resistance that emerges in 40-50% of patients in the metastatic setting after prolonged aromatase inhibitor exposure. There is an unmet need for novel therapeutic approaches to overcome resistance mechanisms and improve outcomes in patients with ER+/HER2- aBC with ESR1 -mutated tumors progressing after ET+CDK4/6i. ELA is a next-generation oral SERD that binds to ER-alpha, inducing its degradation. In EMERALD, ELA improved PFS vs SOC ET in patients with ESR1 -mutated tumors (HR 0.55; 95% CI 0.39-0.77; P=0.0005) [Bidard 2022]. Differences were notable among patients who received prior ET+CDK4/6i ≥12 mo; median PFS with ELA was 8.6 mo vs 1.9 mo with SOC ET (HR 0.41; 95% CI 0.26-0.63) [Bardia 2024]. Crosstalk between ER and PI3K/AKT/mTOR pathways provides a rationale for evaluating ELA+EVE (a mTORC1 inhibitor). In ELEVATE phase 1b (NCT05563220), ELA+EVE demonstrated ORR 22% and CBR at 24 weeks 72% in patients with ER+/HER2- aBC progressing after ET+CDK4/6i; ELA 345 mg + EVE 7.5 mg was identified as the RP2D [Rugo ESMO 2024]. Safety was consistent with the known profile of EVE+SOC ET. ADELA compares ELA+EVE vs ELA+PBO in ER+/HER2- aBC patients with ESR1- mutated tumors progressing on ET+CDK4/6i. Methods: ADELA (NCT06382948) is an international, multicenter, double-blind, placebo-controlled phase 3 trial. Eligible patients are adults (≥18 yrs) with ER+/HER2- aBC and ESR1 -mutated tumors, previously treated with 1-2 lines of ET for aBC, and evidence of disease progression on prior ET+CDK4/6i for aBC after ≥6 mo. Patients receiving CDK4/6i-based adjuvant therapy are eligible (disease progression must be confirmed after ≥12 mo of treatment but <12 mo following CDK4/6i completion). Other criteria include adequate organ function and ECOG PS 0-1. Exclusion criteria include prior chemotherapy for aBC and active uncontrolled/symptomatic brain metastasis. Patients will be randomized 1:1 to 28-d cycles of ELA 345 mg + EVE 7.5 mg QD or ELA 345 mg + PBO QD until disease progression or unacceptable toxicity. Patients will receive dexamethasone mouthwash during the first 8 wks. Stratification factors are presence of visceral metastases (yes vs no) and duration of prior CDK4/6i (≥12 mo vs <12 mo). The primary objective will be to evaluate PFS based on blinded independent review committee. Secondary endpoints include investigator-assessed PFS, OS, ORR, CBR, DoR, TTR, best percentage change in tumor burden, safety, and HRQoL. Status: Planned enrollment is 240 patients; recruitment is ongoing. Clinical trial information: NCT06382948 .
Background:A phase 3b extension of the ZOE-50/70 trials evaluated long-term efficacy, immunogenicity, and safety of the recombinant zoster vaccine (RZV) in participants ≥50 years, with a 6-year follow-up after completion of the primary studies. A subset of participants was evaluated for immunogenicity and safety of 1 or 2 additional doses administered 5-6 years after primary vaccination. Methods:Participants were randomized to 1 additional dose (1-additional dose group, n = 61), 2 additional doses (revaccination group, n = 60), or no additional vaccination (control, n = 119). Humoral and cell-mediated immunity were evaluated by antiglycoprotein E (gE) antibodies, gE-specific CD4[2+] T-cells, and memory B-cells. Reactogenicity was evaluated for 7 days postvaccination and overall safety was evaluated throughout the study. NCT02723773. Results:Anti-gE geometric mean concentrations (GMCs) were 10 000-11 500 mIU/mL in all groups preadditional vaccination. Geometric mean concentrations peaked at 1 month after 1 dose (73 834.4 and 79 419.8 mIU/mL in the 1-additional dose and revaccination groups, respectively), declined at Year 1, but remained above preadditional vaccination levels thereafter. Geometric mean concentration was 64 603.0 mIU/mL 1 month after the second dose in the revaccination group. Geometric mean concentrations in the control group were 8825.4 mIU/mL at Year 1 and 6858.8 mIU/mL at Year 6. The frequency of gE-specific CD4[2+] T-cells and memory B-cells followed a similar pattern. Pain and fatigue were the most common solicited adverse events. No serious adverse events related to RZV were reported. Conclusions:A single additional RZV dose elicited strong and durable humoral and cell-mediated anamnestic responses, with a reactogenicity and safety profile as established in primary studies. Clinical Trial Registration:NCT02723773.
The anatomical site of gluteal administration may influence the pharmacokinetics and tolerability of long-acting cabotegravir (CAB) plus rilpivirine (RPV), but direct comparisons between dorsogluteal (DG) and ventrogluteal (VG) injections are limited. In this prospective intra-individual crossover study, 152 adults with HIV receiving injectable CAB and RPV were switched from DG to VG administration. A total of 842 trough and 131 one-month postinjection plasma samples were analyzed. VG delivery was associated with higher one-month post-dose concentrations for both drugs (median CAB 1280 vs. 834 ng/mL, p < 0.001; RPV 148 vs. 126 ng/mL, p = 0.043). At trough, CAB concentrations were lower with VG injections (573 vs 664 ng/mL, p < 0.001), whereas RPV levels did not differ significantly (131 vs 123 ng/mL, p = 0.461). Although uncommon, a higher proportion (6.9% vs. 1.5%, p = 0.001) of CAB trough samples fell below the protein-adjusted inhibitory concentration 90 threshold in the VG group. VG administration resulted in lower variability in pooled CAB and RPV trough concentrations, both intra-patient (standard deviation ratio 0.92; p = 0.041) and inter-patient (0.80; p = 0.001), compared with DG injections. Detectable HIV-1 RNA (≥50 copies/mL) was rare and comparable between injection sites, with no confirmed virologic failures. Participants reported better tolerability with VG injections, which were associated with fewer local symptoms and were preferred by 67% of respondents. Ventrogluteal administration is associated with more consistent pharmacokinetics and improved tolerability, supporting its use as the preferred site for long-acting CAB/RPV. Although CAB trough levels were modestly lower and occasionally fell below predefined thresholds with VG injection, this did not impact virologic outcomes, reinforcing its clinical suitability in most settings.
Purpose: To explore anatomically adjusted point-to-point relationships between macular sensitivity and intraretinal layer thickness in healthy and glaucomatous eyes using combined optical coherence tomography (OCT) and microperimetry. Methods: Seventy-two eyes were included (27 healthy controls and 45 eyes with primary open-angle glaucoma). Retinal sensitivity was assessed using MP-1 microperimetry, and retinal structure was evaluated with Spectralis OCT. Automatic segmentations included macular retinal nerve fiber layer (mRNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), GCL + IPL, ganglion cell complex (mRNFL + GCL + IPL), and the outer retinal layer. Microperimetry maps were anatomically aligned with OCT grids using vascular landmarks, and ganglion cell displacement was considered when analyzing inner retinal layers. Thickness measurements were obtained at corresponding anatomical points, and structure-function associations were assessed using Spearman correlation analysis to generate spatial correlation maps. Results: Almost no significant pointwise correlations were detected in healthy eyes across any retinal segmentation. In glaucomatous eyes, significant positive correlations were observed for inner retinal layers, whereas no significant associations were found for the outer retinal layer. Distinct spatial patterns were identified, with peripheral correlations for mRNFL and paracentral temporal correlations for GCL, IPL, and GCL + IPL. The highest number of significant associations was observed for the ganglion cell complex. Conclusions: Anatomically adjusted pointwise analysis revealed localized and heterogeneous patterns of macular structure-function coupling predominantly involving ganglion cell-related layers in glaucoma. High-resolution mapping may uncover spatial relationships that are partially obscured by regional or spatially averaged approaches and should be interpreted as a complementary exploratory strategy rather than a replacement for established regional analyses.
Background Population ageing and the rise in chronic diseases are driving a shift from residential models to home care where family carers play a key role. Although education programmes have shown benefits, limited attention has been paid to how family caregivers can be effectively trained to prevent unintentional mistakes in home care and to how they should be prepared to respond to them related to the care they provide.Objectives This scoping review aims to examine education programmes that enhance family caregivers’ knowledge and skills to promote safe home care, prevent unintentional mistakes and mitigate their impact on both care recipients and family caregivers.Design This study follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) methodology for scoping reviews.Data sources Comprehensive searches were conducted in PubMed, Scopus and Embase in April 2024.Eligibility criteria The review included studies on family caregivers in home-based care, focusing on education programmes promoting safe practices; quantitative, qualitative and mixed-methods designs were eligible while studies on professional care or unrelated to home safety were excluded.Data extraction and synthesis Extracted data included study characteristics, education type, target population and safety-related outcomes, which were summarised descriptively to map the available evidence.Results 31 studies on home safety education programmes for family caregivers across oncological, neurological, chronic and paediatric conditions were identified, mostly from the USA and conducted in hospital, home and other health and care facilities. Randomised controlled trials predominated and were generally high quality. Education programmes targeting technical, daily living and self-care skills improved caregiver burden, knowledge, preparedness and quality of life although physical health outcomes showed limited change.Conclusions Evidence indicates that structured education programmes enhance family caregivers’ knowledge, preparedness, competence and psychological well-being, supporting safer home care. While current education programmes are mostly short-term and caregiver-centred, this review identifies core technical, daily life and self-care competencies to guide future education programmes, highlighting the need for co-designed, rigorously evaluated education programmes that include patient safety outcomes and caregiver emotional support.